The association of medication-related osteonecrosis of the jaw with *Actinomyces spp.* infection

Guenter Russmueller1, Rudolf Seemann1, Kathrin Weiss2, Victoria Stadler1, Manuel Speiss1, Christos Perisanidis1, Thorsten Fuereder2, Birgit Willinger3, Irene Sulzbacher4 & Christoph Steininger2

Medication-related osteonecrosis of the jaw (MRONJ) represents a complication of bisphosphonate treatment that responds poorly to standard treatment. In a retrospective cohort study we investigated a possible role of *Actinomyces spp.* in the pathogenesis of MRONJ. Deep biopsies of necrotic bone were collected during surgical treatment of MRONJ and evaluated by histology and microbiology for the presence of *Actinomyces spp.* Microbiological, demographic and clinicopathological data were analyzed for risk of *Actinomyces*-associated MRONJ. Between 2005 and 2014, 111 patients suffering from histologically-confirmed MRONJ were identified. *Actinomyces spp.* were detected in 99 cases (89%) by histology and in six further patients by microbiological culture. A diverse microbial flora was found in all specimens without association with *Actinomyces spp.* Demographic and clinicopathological characteristics did not separate significantly *Actinomyces*-positive from *Actinomyces*-negative cases. Our observations confirm previous reports of a high prevalence of *Actinomyces spp.* in MRONJ in the single largest cohort available up to now. The high prevalence of *Actinomyces spp.* and the lack of clinicopathological risk factors underline the prominent role of *Actinomyces spp.* in MRONJ and may change the current understanding of MRONJ. Established prolonged antimicrobial treatment regimens against *Actinomyces spp.* infection could therefore be a mainstay of future MRONJ management.
with intravenous bisphosphonates as well as combination treatment with anti-angiogenetic drugs were identified as significant risk factors for MRONJ.  

Still, bisphosphonate treatment may not explain exclusively the observed predilection of the jaw of cancer patients. Remodeling or oversuppression of bone resorption, inhibition of blood supply, constant microtrauma, dental/periodontal surgery, or local inflammation were proposed in association with bisphosphonate treatment to explain the unique localization to the jaw but none of these hypotheses explain all cases. Evidence suggesting a role of Actinomyces species in the evolution of MRONJ accumulated over the past years, but these small case series and reviews revealing a high prevalence of Actinomyces spp. in MRONJ did not had impact on current treatment recommendations up to now. 

Actinomyces spp. are Gram-positive, facultative anaerobic, non-spore-forming and commonly filamentous microorganisms. Actinomyces spp. are commensals of the mucosa of oropharynx, gastrointestinal tract and female genital tract. Nevertheless, in case of breaches to the mucosal barrier by trauma, surgical procedures, or foreign bodies, microbes may invade deep tissue structures and cause a difficult to treat, chronic-progressive disease termed Actinomycosis. Standards of treatment for invasive actinomycosis have been developed, validated and adapted during the past five decades and is based on prolonged antimicrobial treatment for 2–6 months combined with surgery. The anatomic region affected (e.g. cervicofacial, pulmonal, abdominal) is not associated with a requirement to adapt antimicrobial treatment duration.  

The aim of the present study was to evaluate in a large and well-characterized cohort of patients suffering from MRONJ the incidence of Actinomyces spp. infection and possible risk-factors that may predispose patients to this infection. Contrary to expectation, a large majority of the present MRONJ cases was associated with Actinomyces spp. infection.

### Materials and Methods

#### Study population.

The present retrospective study of Actinomycosis associated with MRONJ included all consecutive patients suffering from MRONJ and who were treated at the Department of Oral- and Maxillofacial Surgery, at the Medical University of Vienna, between 2005 and 2014. Inclusion criteria were clinically diagnosed MRONJ according the current guidelines of the American Association of Oral and Maxillofacial Surgeons (AAOMS), current or previous treatment of malignancy or osteoporosis with a bisphosphonate. Accordingly, the clinical diagnosis of MRONJ was defined as presence of exposed necrotic bone of maxilla or mandible, with or without pain and signs and symptoms of superinfection, for more than eight weeks without tendency of spontaneous healing. Patients were excluded from the study when having received radiotherapy, bone biopsy was not available for histological evaluation, or the clinically suspected diagnosis could not verified by histology. Staging of confirmed cases of MRONJ was done in respect of clinical symptoms and severity of the disease from Stage 0 to Stage 3 according to AAOMS guidelines. Stage 0 cases were not included as they are characterized by non-specific symptoms or radiographic findings without featuring exposed necrotic bone. Treatment of the Stage 1 to 3 MRONJ cases followed an established algorithm combining conservative pre-treatment followed by surgical removal of necrotic bone and soft tissue closure. Sample collection for histology was performed in all cases during the surgical standard procedure. According to this standard treatment algorithm, all patients received systemic antibiotic treatment with amoxicillin (2 × 1 g/24 hours)/clavulanic acid (2 × 500 mg/24 hours) or clindamycin (3 × 300 mg/24 hours) for approximately 4 weeks between admittance and surgery.  

Demographic, clinicopathological and follow-up data were extracted retrospectively from the Vienna General Hospital Patient Information System (AKIM). The study protocol was approved by the Ethics Committee of the Medical University of Vienna, Austria (ECS 1824/2015) and all study related procedures were done according to the declaration of Helsinki. Due to the retrospective cohort study design, no informed consent had to be obtained by approval of the ethics committee.

#### Histological and microbiological analysis.

The specimens retrieved under surgical treatment of MRONJ comprised of deep bone samples for analysis by histology and microbiology in all cases. The respective specimens were divided into two aliquots and either fixed in 4% phosphate-buffered saline (PBS)-formalin and decalcified with use of ethylenediaminetetraacetic acid (EDTA) for 7 days for histological analysis or immediately transferred with use of ethylenediaminetetraacetic acid (EDTA) for 7 days for histological analysis or immediately transferred into reduced transport medium (Port-A-Cul™, Becton, Dickinson and Company, NJ, USA) and transported to microbiological laboratory for microbiological culture. 

For histological analysis, specimens were then embedded in paraffin, cut into 2 μm thick slices and stained by hematoxylin and eosin (H&E). To highlight Actinomyces spp., the specimens were stained additionally by periodic acid-Schiff (PAS), Gram and Grocott’s methenamine silver stain (GMS). The slides were examined by a trained pathologist for pathognomonic features of actinomycosis (sulfur granules) and photographed by light microscopy (Fig. 1).  

For microbiological culture, specimens were streaked to blood agar, chocolate agar, and Sabouraud Dextrose-Agar and were incubated at 29°–31 °C as well as 35°–37 °C. For the growth of anaerobic bacteria, Brucella agar (Becton Dickinson, Heidelberg, Germany) was inoculated and incubated at 35°–37 °C under anaerobic conditions for 21 days in total. In case of growth, identification was performed either biochemically using Vitek® (bioMérieux, Marcy l’Etoile, France) or MALDI-TOF (Bruker, Bremen, Germany). If these methods were unsuccessful, isolates were identified by 16S sequence analysis (Fig. 1).  

#### Statistical analysis.

The primary endpoint of this study was the prevalence of MRONJ-related actinomycosis within the study population as confirmed by histology. Secondary objectives were to determine clinicopathological risk factors for the development of MRONJ-related actinomycosis by means of logistic regression models. The models including one factor were compared to the null model using a likelihood ratio test and thus providing the p-values. The distribution of bisphosphonate drugs in the actinomyces positive and the negative group was
tested for count distribution by means of a chi-squared test instead of applying logistic regression. Furthermore, a Fisher’s exact test was used to investigate the allocation of microbiological culture results between actinomyces positive and the negative cases in histology. A p-value of $<0.05$ was defined as statistically significant. All calculations were performed using the statistical programming environment “R” (version 2.15.1, Vienna, Austria). Finally all p-values were corrected for multiple testing using Bonferroni adjustment.

Results

Demographic, clinical and histological results. A total of 150 patients fulfilling the clinical criteria of MRONJ were identified during the study period of 2005 to 2014. Of these patients, 39 cases were excluded from the study because of a previous history of radiotherapy ($n = 6$), unavailable bone specimen for histological analysis ($n = 24$), or histological evaluation not supporting the clinical diagnosis ($n = 9$). The final cohort of 111 patients with clinically diagnosed and histologically confirmed MRONJ were predominantly female, above the age of 65 years, and all were Caucasian (Table 1). The majority of MRONJ patients had a malignancy as underlying disease and most of them suffered from malignant bone disease. MRONJ was diagnosed in most patients at a clinical stage 2 ($n = 55$) or stage 1 ($n = 43$). Thirteen patients had stage 3 disease. The predominant location of MRONJ was in the mandibular bone ($n = 72$), followed by the maxilla ($n = 34$) or both ($n = 5$).

The clinical presentation of MRONJ was uniformly a white-yellowish areas of exposed necrotic bone, sometimes accompanied erythema of the mucosa or gingival tissue surrounding the lesion (Fig. 2). Uncharacteristic for “classical” Actinomycosis, sinus formation with affection of oro-pharyngeal soft tissue was not noticed for the present patients.

Histological evaluation of the bone specimens collected in the course of surgical treatment showed the presence of *Actinomyces spp.* in 99 of 111 (89%) MRONJ cases. The pathognomonic features of *Actinomyces spp.* infection was found in all histopathological samples, including aggregates composed of *Actinomyces spp.* filaments (sulfur granules), sun-ray morphology of these granules and accompanying inflammatory tissue reaction. Microbiological evaluation of the bone specimens collected in parallel was uniformly negative for *Actinomyces spp.* with only seven exceptions (Table 2). In one MRONJ case with an *Actinomyces*-negative histology result, the pathogen could be cultured from the bone specimen. A diverse microbial flora could be cultured from all but 7 (6%) of the 111 specimens including apathogenic residential oral flora, anaerobic mixed flora and facultative pathogenic microbes. The most commonly facultative pathogens cultured belonged to the families of *Enterobacteriaceae*, *Neisseriaceae*, and *Streptococcaceae*. The relative frequency of microbes cultured did not differ significantly between *Actinomyces spp.* positive and negative cases of MRONJ.

To evaluate potential risk factors for *Actinomyces*-associated MRONJ, patients were compared with respect to selected demographic and clinicopathological characteristics (Table 3). In this analysis, none of the parameters evaluated separated patients positive for *Actinomyces spp.* clearly from those without detectable infection.
Discussion

MRONJ affects up to 10% of cancer patients treated with antiresorptive drugs. The disease is associated with significantly increased morbidity and decreased quality of life. Treatment is associated with high rates of treatment failures and recurrences. Prophylactic and therapeutic strategies are impeded by the very limited understanding of pathomechanisms relevant to the evolution of MRONJ. In the present study, we substantiate previous evidence that a large majority of MRONJ lesions are infected by Actinomyces spp. We failed to identify clear risk factors for Actinomyces spp. positivity in MRONJ cases – possibly because of the small number of Actinomyces spp. negative cases. As a consequence of these results, current recommendations may have to be revised and adapted to the observation that MRONJ is frequently associated with invasive Actinomyces spp. infection.

Table 1. Demographics of the MRONJ study population.

| Characteristic                  | Patients with MRONJ (n = 111) |
|--------------------------------|--------------------------------|
| Mean age (SD), years           | 69 (10)                        |
| Gender, no. (%)                |                                |
| Male                           | 42 (38)                        |
| Female                         | 69 (62)                        |
| Underlying disease, no. (%)    |                                |
| Osteoporosis                   | 26 (23)                        |
| Cancer                         | 85 (77)                        |
| Malignant bone disease, no. (%)| 74 (67)                        |
| MRONJ Staging, no. (%)         |                                |
| Stage 0                        | 0 (0)                          |
| Stage 1                        | 43 (39)                        |
| Stage 2                        | 55 (49)                        |
| Stage 3                        | 13 (12)                        |
| Location of MRONJ, no. (%)     |                                |
| Mandible                       | 72 (64)                        |
| Maxilla                        | 34 (31)                        |
| Both                           | 5 (5)                          |

Figure 2. Clinical findings in patients suffering from MRONJ showing necrotic alveolar bone (Stage 1) distal to a premolar tooth (a) or large areas of exposed bone with sings of infection (Stage 2) caused by tooth extractions under bisphosphonate therapy (b). Despite no large portion of necrotic bone in the maxilla (c), Stage 3 is characterized by severe infection leading to maxillary sinusitis in the presented case (d).
commonly recovered along with Actinomyces spp. Cess achieved in early studies with low-dose penicillin G and a mixed flora of anaerobic and aerobic pathogens skin infections. Actinomycosis is generally considered an uncommon disease that affects patients of all ages and neck are the most common sites of actinomycosis in humans followed by thoracic, abdomino-pelvic, cerebral and draining sinuses and unresponsiveness to empiric antimicrobial therapy of a presumed abscess. The face and fer significantly. Classical actinomycosis manifests clinically as chronic, granulomatous abscess with tissue fibrosis and visible sulphur granules that are pathognomonic for classical actinomycosis are not visible in MRONJ-associated actinomycosis. Actinomyces spp. actinomycosis affects primarily cancer patients and is limited in most cases to the jaw bone. Macroscopically visible sulphur granules that are pathognomonic for classical actinomycosis are not visible in MRONJ-associated actinomycosis. Risk factors identified presently in association with detection of Actinomyces spp. are fastidious and successful isolation requires culture of specimens under anaerobic or microaerophilic conditions for prolonged periods. Sensitivity of culture is further reduced significantly by antimicrobial treatment of patients before sample collection which was the case in most of the present patients. To increase detection rates by microbial culture, antimicrobial therapy should be discontinued for a few weeks before surgery and collection of clinical samples. Nevertheless, cessation of antimicrobial treatment is difficult to be justified giving the risk of progression and the high sensitivity and specificity of histopathology for the diagnosis of actinomycosis. Antimicrobial treatment before sample collection also changes very likely the oropharyngeal microbiome and microbiological culture results have to be interpreted with caution in bone samples collected from MRONJ cases.

In contrast to microbiological culture, detection of the Actinomyces spp. by histology together with pathognomonic sulfur granules and signs of subacute or chronic inflammation, granulation tissue, and osteonecrosis substantiate a possible causal link. Actinomyces spp. may be detected reliably in affected bone specimens because of their morphologic appearance upon staining with PAS, Gram and GMS. Nevertheless, histology requires at least several days to provide a reliable diagnosis. In addition, large and high-quality bone specimens are required for a reliable histological diagnosis. The focus of the present study on patients from whom a sufficiently large bone specimen was available for histological evaluation may be associated with a selection bias towards cases of more severe disease that more likely are treated by respective surgery. A rapid diagnosis with epidemiological information on antimicrobial resistance patterns of clinical isolates is important for treatment success. Accordingly, novel assays for the fast and reliable diagnosis of Actinomyces-associated MRONJ are urgently required.

The clinical presentation of “classical”, oropharyngeal actinomycosis and MRONJ-associated actinomycosis differ significantly. Classical actinomycosis manifests clinically as chronic, granulomatous abscess with tissue fibrosis and draining sinuses and unresponsiveness to empiric antimicrobial therapy of a presumed abscess. The face and neck are the most common sites of actinomycosis in humans followed by thoracic, abdomino-pelvic, cerebral and skin infections. Actinomycosis is generally considered an uncommon disease that affects patients of all ages and can appear in both immunocompetent and immunocompromised individuals. MRONJ-associated actinomycosis affects primarily cancer patients and is limited in most cases to the jaw bone. Macroscopically visible sulphur granules that are pathognomonic for classical actinomycosis are not visible in MRONJ-associated actinomycosis. Risk factors identified presently in association with detection of Actinomyces spp. have to be interpreted with caution in view of the small numbers of Actinomyces-negative patients. Hence, MRONJ-associated actinomycosis differs in terms of optimum diagnostic approach and clinical presentation clearly from classical oro-pharyngeal actinomycosis.

To attain an optimum treatment success, the antimicrobial regimen for actinomycosis-associated MRONJ prior to surgery still has to be defined despite the exquisite sensitivity of Actinomyces spp. to betalactam agents. Smith et al. proposed as possible scheme for the antibiotic treatment of cervicofacial actinomycoses may consist of amoxicillin plus clavulanic acid or also ampicillin plus sulbactam based on the frequent detection of mixed infections. The rational mentioned for this broad-spectrum antimicrobial treatment was poor treatment success achieved in early studies with low-dose penicillin G and a mixed flora of anaerobic and aerobic pathogens commonly recovered along with Actinomyces spp. In our experience, however, patients with orocervicofacial

| Taxonomic family | Actinomyces spp. detection by histology (n = 111) | OR | p-value* | Adjusted p |
|------------------|-----------------------------------------------|----|----------|------------|
| Anaerobic mixed flora | 22 (20) 5 (5) | 0.4 | 0.160 | 1.0 |
| Residential oral flora | 25 (23) 5 (5) | 0.5 | 0.301 | 1.0 |
| Actinomycetaceae | 6 (5) 1 (1) | 0.7 | 0.561 | 1.0 |
| Bacteroidaceae | 8 (7) 1 (1) | 1 | 1,000 | 1.0 |
| Clostridiaceae | 4 (4) 0 (0) | Inf | 1,000 | 1.0 |
| Enterobacteriaceae | 26 (23) 6 (5) | 0.4 | 0.101 | 1.0 |
| Enterococcaceae | 5 (5) 0 (0) | Inf | 1,000 | 1.0 |
| Lactobacillaceae | 7 (6) 1 (1) | 0.8 | 1.000 | 1.0 |
| Neisseriaceae | 22 (20) 3 (2) | 1.4 | 1.000 | 1.0 |
| Pasteurellaceae | 9 (8) 3 (3) | 0.3 | 0.120 | 1.0 |
| Prevotellaceae | 6 (5) 0 (0) | Inf | 1,000 | 1.0 |
| Saccharomycetaceae | 18 (16) 2 (2) | 1.1 | 1,000 | 1.0 |
| Staphylococcaceae | 4 (4) 1 (1) | 0.5 | 0.442 | 1.0 |
| Streptococcaceae | 34 (31) 3 (3) | 1.6 | 0.747 | 1.0 |
| Others | 5 (5) 0 (0) | Inf | 1,000 | 1.0 |
| No growth | 7 (6) 0 (0) | Inf | 1,000 | 1.0 |

Table 2. Microbiological culture results of bone specimens. *Fisher’s Exact.
Betalactam agents have a high therapeutic index which allows safe administration of high doses of drugs and high therapeutic drug levels are achieved in serum, tissues, bile, and synovial fluid. We found recently that *Actinomyces* spp. isolates are universally susceptible to betalactam antimicrobial agents. Treatment without β-lactamase inhibitor reduces also significantly the rate of gastrointestinal adverse events such as abdominal discomfort or diarrhea for any cause, including *Clostridium difficile* enterocolitis. Accordingly, we recommend for the treatment of actinomycosis in concordance with others the use of a betalactam antimicrobial agent at high daily doses prior to final surgical treatment of MRONJ23. For patients with penicillin allergy, tetracyclines

| Characteristic            | Actinomyces spp. detection by histology | OR (95%-CI) | p-value* | Adjusted p |
|---------------------------|----------------------------------------|-------------|---------|------------|
| Biophosphonate            | Positive, no. (%) Negative, no. (%)    |             |         |            |
| Zoledronate               | 58 (52) 9 (8)                          | —           | 0.830*  | 1.0        |
| Combination therapy       | 19 (17) 2 (2)                          |             |         |            |
| Alendronate               | 11 (10) 1 (1)                          |             |         |            |
| Ibandronate               | 6 (5) 0 (0)                            |             |         |            |
| Risedronate               | 2 (2) 0 (0)                            |             |         |            |
| N/A                       | 2 (2) 0 (0)                            |             |         |            |
| Administration route      | 1.86 (0.22,15.52)                      | 0.540       | 1.0     |            |
| intravenous               | 83 (75) 11 (10)                        |             |         |            |
| oral                      | 14 (12) 1 (1)                          |             |         |            |
| N/A                       | 2 (2) 0 (0)                            |             |         |            |
| Primary disease           | 0.63 (0.13,3.05)                       | 0.545       | 1.0     |            |
| Osteoporosis              | 24 (21) 2 (2)                          |             |         |            |
| Cancer+                   | 75 (68) 10 (9)                         |             |         |            |
| Type of malignancy        |                                        |             |         |            |
| Breast                    | 24 (21) 5 (4)                          |             |         |            |
| Multiple Myeloma          | 16 (14) 5 (5)                          |             |         |            |
| Prostate                  | 13 (11) 0 (0)                          |             |         |            |
| Renal                     | 9 (8) 0 (0)                            |             |         |            |
| Lung                      | 6 (5) 2 (2)                            |             |         |            |
| Others                    | 5 (4) 0 (0)                            |             |         |            |
| Malignant bone disease    | 63 (57) 11 (10)                        | 0.16 (0.02,1.28) | 0.031 | 0.744 |
| Chemotherapy              |                                        | 0.84 (0.09,7.45) | 0.876 | 1.0     |
| Current§                  | 7 (6) 1 (1)                            |             |         |            |
| Former$/Never             | 92 (83) 11 (10)                        |             |         |            |
| Smoking                   |                                        | 6.29 (0.78,50.7) | 0.031 | 0.744 |
| Current                   | 36 (32) 1 (1)                          |             |         |            |
| Former$/Never             | 63 (57) 11 (10)                        |             |         |            |
| Alcohol                   |                                        | 1.78 (0.37,8.67) | 0.452 | 1.0     |
| Yes                       | 26 (23) 2 (2)                          |             |         |            |
| No                        | 73 (66) 10 (9)                         |             |         |            |
| Diabetes                  |                                        | 1.69 (0.35,8.24) | 0.497 | 1.0     |
| Yes                       | 25 (22) 2 (2)                          |             |         |            |
| No                        | 74 (67) 10 (9)                         |             |         |            |
| Obesity                   |                                        | 22028341.47 (0,Inf) | 0.018 | 0.450 |
| BMI > 30                  | 18 (16) 0 (0)                          |             |         |            |
| BMI ≤ 30                  | 63 (57) 12 (11)                        |             |         |            |
| N/A                       | 18 (16) 0 (0)                          |             |         |            |

### Table 3. Risk factors for detection of *Actinomyces spp.* in MRONJ lesions.

| Characteristic | No. (%) | OR (95%-CI) | p-value* |
|---------------|---------|-------------|----------|
| Actinomycosis | 58 (52) | 1.86 (0.22,15.52) | 0.540     |
| Zoledronate   | 52 (46) | 1.78 (0.37,8.67)  | 0.452     |
| Combination therapy | 2 (2) | 1.69 (0.35,8.24) | 0.497     |
| Alendronate   | 38 (34) | 1.78 (0.37,8.67)  | 0.452     |
| Ibandronate   | 6 (5)   | 1.69 (0.35,8.24)  | 0.497     |
| Risedronate   | 2 (2)   | 1.69 (0.35,8.24)  | 0.497     |
| N/A           | 2 (2)   | 1.69 (0.35,8.24)  | 0.497     |
| Administration route | 1 (1) | 1.69 (0.35,8.24) | 0.497     |
| intravenous   | 75 (68) | 1.86 (0.22,15.52) | 0.540     |
| oral          | 1 (1)   | 1.69 (0.35,8.24)  | 0.497     |
| N/A           | 1 (1)   | 1.69 (0.35,8.24)  | 0.497     |
| Primary disease | 1 (1) | 1.69 (0.35,8.24) | 0.497     |
| Osteoporosis  | 68 (60) | 1.86 (0.22,15.52) | 0.540     |
| Cancer+       | 68 (60) | 1.86 (0.22,15.52) | 0.540     |
| Breast        | 21 (18) | 1.69 (0.35,8.24)  | 0.497     |
| Multiple Myeloma | 5 (4) | 1.69 (0.35,8.24) | 0.497     |
| Prostate      | 11 (9)  | 1.69 (0.35,8.24)  | 0.497     |
| Renal         | 8 (7)   | 1.69 (0.35,8.24)  | 0.497     |
| Lung          | 2 (2)   | 1.69 (0.35,8.24)  | 0.497     |
| Others        | 4 (4)   | 1.69 (0.35,8.24)  | 0.497     |
| Malignant bone disease | 10 (9) | 1.69 (0.35,8.24) | 0.497     |
| Chemotherapy  | 83 (75) | 1.86 (0.22,15.52) | 0.540     |
| Current§      | 6 (5)   | 1.69 (0.35,8.24)  | 0.497     |
| Former$/Never | 83 (75) | 1.86 (0.22,15.52) | 0.540     |
| Smoking       | 75 (68) | 1.86 (0.22,15.52) | 0.540     |
| Current       | 32 (28) | 1.69 (0.35,8.24)  | 0.497     |
| Former$/Never | 83 (75) | 1.86 (0.22,15.52) | 0.540     |
| Alcohol       | 57 (49) | 1.69 (0.35,8.24)  | 0.497     |
| Yes           | 23 (20) | 1.69 (0.35,8.24)  | 0.497     |
| No            | 74 (65) | 1.69 (0.35,8.24)  | 0.497     |
| Diabetes      | 67 (58) | 1.69 (0.35,8.24)  | 0.497     |
| Yes           | 22 (19) | 1.69 (0.35,8.24)  | 0.497     |
| No            | 74 (65) | 1.69 (0.35,8.24)  | 0.497     |
| Obesity       | 75 (68) | 1.86 (0.22,15.52) | 0.540     |
| BMI > 30      | 16 (14) | 1.69 (0.35,8.24)  | 0.497     |
| BMI ≤ 30      | 12 (11) | 1.69 (0.35,8.24)  | 0.497     |
| N/A           | 16 (14) | 1.69 (0.35,8.24)  | 0.497     |

actinomycosis respond well to antimicrobial therapy with a betalactam agent only indicative of the low relevance of concomitantly isolated facultative pathogens. Moreover, our present observations may also indicate that cancer patients receiving antiresorptive drugs may benefit from antimicrobial prophylaxis concomitant with dentoalveolar surgery.
are good alternative for oral therapy, especially in milder disease presentations. In severe infections, carbapenems or the newer compound tigecyclin may be appropriate therapeutic options.

In conclusion, we found that MRONJ is very frequently associated with the detection of Actinomyces spp. by histological evaluation of specimens from necrotic bone. The generally limited sensitivity of histology for the detection of microbes may have further underestimated the factual incidence of Actinomycosis in these patients. The observation of a frequent infection of necrotic bone by Actinomyces spp. may suggest that standard surgical treatment of MRONJ may be complemented by antimicrobial treatment.

References
1. Edwards, B. J. et al. Pharmcovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. The Lancet. Oncology 9, 1166–1172 (2008).
2. Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 72, 1938–1956 (2014).
3. Fliefel, R., Troitsch, M., Kühnisch, J., Ehrenfeld, M. & Otte, S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 44, 568–585 (2015).
4. Estilo, C. L. et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. The Oncologist 13, 911–920 (2008).
5. Saad, E., Chi, K. & Fleshner, N. The role of bisphosphonates in the management of bone metastases in prostate cancer. The Canadian Journal of Urology 11, 2376–2382 (2004).
6. Letocha, A. D. et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20, 977–986 (2005).
7. Bamias, A. et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23, 8580–8587 (2005).
8. Aragon-Ching, J. B. et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-androgentic agents. Cancer Invest 27, 221–226 (2009).
9. Allen, M. R. & Burr, D. B. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67, 61–70 (2009).
10. De Cruylère, J., Tacconelli, E. & Vandecasteele, S. J. Actinomyces osteomyelitis in bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link? European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 33, 1873–1880 (2014).
11. Lee, C. Y., Pien, F. D. & Suzuki, J. B. Identification and treatment of bisphosphonate-associated actinomycotic osteonecrosis of the jaws. Implant Dent 20, 331–336 (2011).
12. Schimpmann, S. et al. Osteopathology associated with bone resorption inhibitors - which role does Actinomyces play? A presentation of 51 cases with systematic review of the literature. J Oral Pathol Med 42, 587–593 (2013).
13. Badros, A. et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24, 945–952 (2006).
14. Moghimi, M., Salentijn, E., Debets-Ossenkop, Y., Karagözoglu, K. H. & Forouzanfar, T. Treatment of cervicofacial actinomycosis: a report of 19 cases and review of literature. Med Oral Patol Oral Cir Bucal 18, e627–e632 (2013).
15. Steininger, C. & Willinger, B. Resistance patterns in clinical isolates of pathogenic Actinomyces species. J Antimicrob Chemother 71, 422–427 (2016).
16. Wutzl, A. et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 30, 1224–1230 (2008).
17. Holzinger, D. et al. Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJ). Oral Oncol 49, 66–70 (2013).
18. Hansen, T. et al. Actinomycosis of the jaws--histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451, 1009–1017 (2007).
19. Lo Muzio, L. et al. The contribution of histopathological examination to the diagnosis of cervico-facial actinomycosis: a retrospective analysis of 68 cases. European Journal of Clinical Microbiology & Infectious Diseases: official publication of the European Society of Clinical Microbiology 33, 1915–1918 (2014).
20. Migliorati, C. A., Siegel, M. A. & Elting, L. S. Bisphosphonate-associated osteonecrosis of the jaws: a long-term complication of bisphosphonate treatment. The Lancet. Oncology 7, 508–514 (2006).
21. Reid, I. R. Osteonecrosis of the jaw: who gets it, and why? Bone 44, 4–10 (2009).
22. Holmberg, K., Nord, C. E. & Dornbusch, K. Antimicrobial in vitro susceptibility of actinomycesiisraelii and arachnax propionica. Scandinavian journal of infectious diseases 9, 40–45 (1977).
23. Smego, R. A. Jr. & Foglia, G. Actinomycosis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 26, 1255-1261; quiz 1262-1253 (1998).
24. Kononen, E. & Wade, W. G. Actinomycosis and related organisms in human infections. Clinical microbiology reviews 28, 419–442 (2015).
25. Peabody, J. W. Jr & Seabury, J. H. Actinomycosis and nocardiosis. A review of basic differences in therapy. Am J Med 28, 99–115 (1960).
26. Nedomansky, J., Weiss, D., Willinger, B., Nickl, S. & Steininger, C. Acne inversa complicated by Actinomycosis neuii. Infection 2015.
27. Wong, V. K., Turmezei, T. D. & Weston, V. C. Actinomycosis. BMJ 343, 6099 (2011).
28. Smith, A. J., Hall, V., Thakker, B. & Gemmell, C. G. Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agents. J Antimicrob Chemother 56, 407–409 (2005).
29. Martin, M. V. Antimicrobial treatment of cervicofacial actinomycosis for patients allergic to penicillin: a clinical and in vitro study. Br J Oral Maxillofac Surg 23, 428–434 (1985).

Acknowledgements
The authors would like to thank Ms. Andrea Graf for her work in the microbiological laboratory and figure provision.

Author Contributions
G.R.,C.S., C.P. and T.P. wrote the main manuscript. R.S. performed the complete statistical analysis. K.W., V.S. and M.S. were responsible for data acquisition and processing. B.W. and I.S. provided histological and microbiological data and figures. All authors reviewed the manuscript.
Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Russmueller, G. et al. The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci. Rep. 6, 31604; doi: 10.1038/srep31604 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016